SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

soticlestat

LGND·Ligand Pharmaceuticals
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 3 (completed; results missed primary endpoints)
Time to market
Uncertain and distant: the drug failed Phase 3 and is being restarted by a private company that has not disclosed its clinical development timeline or regulatory strategy.
Why 2/10
Soticlestat has no scheduled PDUFA date, pivotal readout, or other hard binary catalyst in the next ~12 months. The drug is now owned by a private Perceptive Advisors-backed company that has not disclosed its clinical development plan. For LGND, which holds only a 13% passive royalty interest, this asset is a minor component of a diversified 200+ asset portfolio.
Actionable Insight NEUTRAL

Ligand holds a passive 13% royalty/milestone interest in soticlestat, a drug that failed Phase 3 trials and was abandoned by Takeda before being revived by a private Perceptive Advisors-backed NewCo in August 2026. There is no near-term binary catalyst for this asset; the new private sponsor has not disclosed its clinical timeline. For LGND investors, soticlestat is a tail-risk option on a revived program, not a core value driver.

Price Chart

Loading chart...

Executive Summary

Soticlestat (TAK-935/OV-935) is an experimental epilepsy drug that inhibits the cholesterol 24-hydroxylase enzyme. It failed two Phase 3 trials (SKYLINE in Dravet syndrome, SKYWAY in Lennox-Gastaut syndrome) in June 2024, and Takeda formally discontinued the program in January 2025 after the FDA questioned the data package. In August 2026, Perceptive Advisors launched a private company that acquired global rights from Ovid and Takeda, with Ovid eligible for up to $294.5 million in milestones plus royalties. Ligand Pharmaceuticals holds a 13% interest in Ovid's soticlestat royalty and milestone stream, acquired for $30 million in 2023. For LGND shareholders, soticlestat is a minor, passive, long-shot interest within a broadly diversified royalty portfolio of 200+ assets. No near-term binary catalyst exists.

How It Works

Soticlestat is a small molecule that blocks an enzyme called cholesterol 24-hydroxylase (CH24H). By inhibiting this enzyme, it reduces a brain-specific cholesterol metabolite that can overstimulate neurons, with the goal of reducing seizures in people with rare, severe forms of epilepsy that do not respond to standard medications.

Trial Status

Two Phase 3 trials completed in 2024: SKYLINE (Dravet syndrome) and SKYWAY (Lennox-Gastaut syndrome) both missed their primary endpoints. Takeda discontinued the program in January 2025. In August 2026, Perceptive Advisors launched a private NewCo that acquired global rights and plans to continue development with a potentially revised trial design.

The Two-Sided Case

▲ Bull Case4
The Phase 3 SKYLINE study narrowly missed its primary endpoint (p=0.06) and showed statistically significant results in several key secondary efficacy endpoints, suggesting the mechanism may still be viable with a better trial design.
Perceptive Advisors, a sophisticated life sciences investor, chose to back the asset, signaling that it believes the FDA's concerns were about trial design flaws rather than the drug's underlying mechanism or safety profile.
The drug retains FDA orphan drug designations for both Dravet syndrome and Lennox-Gastaut syndrome, which provide market exclusivity and development incentives if ultimately approved.
Ligand acquired its 13% interest for only $30 million in 2023, so the downside is already capped at that amount while any future success would generate passive upside with no additional capital commitment.
▼ Bear Case4
Soticlestat failed both Phase 3 SKYLINE (Dravet syndrome) and SKYWAY (Lennox-Gastaut syndrome) trials, missing primary endpoints in June 2024, leading Takeda to discontinue the program in January 2025 after the FDA flagged data shortcomings.
A 2026 structure-activity relationship study in the journal Molecules noted that soticlestat suffers from 'unsatisfactory in vivo potency' in animal models and clinical trials, raising questions about the drug's fundamental profile.
The drug is now controlled by a private company with no disclosed clinical development timeline or funding details, making the path to potential milestone payments highly uncertain and distant.
For Ligand specifically, soticlestat represents a tiny fraction of its 200+ asset royalty portfolio; even if revived successfully, the 13% interest on Ovid's already-modest royalty share would contribute minimally to LGND's revenue.

Upcoming Catalysts

  • No near-term binary catalysts scheduled; the private NewCo has not disclosed its clinical development timeline or regulatory submission plans.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Ligand Pharmaceuticals PRESS-RELEASE LGND ·Originating report

Sources · 10

Hover a chip for the title
1 en.wikipedia.org2 takeda.com3 takeda.com4 techtimes.com5 investor.ligand.com6 bioworld.com7 endpoints.news8 thepharmacloseout.com9 fiercebiotech.com10 investors.ovidrx.com